Clinical Trial: Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase Inhibitor

U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07832383) titled 'Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase Inhibitor' on Sept. 16.

Brief Summary: This study is designed to evaluate the efficacy on improving cognitive performance as well as the safety, tolerability, and pharmacokinetics (PK) of NBI-1117567 administered once daily (QD) in adults with mild to moderate AD who are receiving stable treatment with an acetylcholinesterase inhibitor.

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: Alzheimer's Disease

Intervention: DRUG: NBI-1117567

NBI-1117567 will be administered per schedul...